All In Biotech

Drug Trial Radar · NCT06181227

A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema

A Phase 2 Study to Evaluate the Safety and Treatment Effect of Intravitreal AVD-104 in Participants With Diabetic Macular Edema

Last checked: Nov 19, 2026Latest source record: Jul 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

21

Actual

Start

Nov 30, 2023

Primary completion

Apr 5, 2024

Study completion Apr 5, 2024

Sponsor

Lead sponsor
Aviceda Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2 study to determine the safety and preliminary efficacy of intravitreal injections of AVD-104, a novel glyco-mimetic nanoparticle, in reducing macular edema associated with diabetic retinopathy.

Conditions

  • Diabetic Macular Edema
  • Diabetic Retinopathy

Interventions

  • AVD-104Drug

    An intravitreal injection of 50 microliters at the doses described will be given. Visual acuity, optical coherence tomography thickness and vascular perfusion will be evaluated for an effect of the drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Serious Adverse EventsTime frame: 3 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Erie Retina Research

    Erie, Pennsylvania

  • Texas Retina Associates

    Dallas, Texas

  • West Texas Retina Consultants

    Wichita Falls, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.